Lexaria Bioscience Corp. (NASDAQ: LEXX), a Global Innovator in Drug Delivery Platforms
Lexaria’s patented DehydraTECH technology proved effective for sildenafil delivery in animal study PDE5-A21-1 The company also made some notable strides with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD By doing so, it hopes to capitalize on the growing cardiovascular drugs market, which is projected to be valued at $107.8 billion by 2025 (https://cnw.fm/8bk1Y) With the success of its studies thus far, the company seeks to conduct even more trials over the 2022 calendar year Lexaria Bioscience (NASDAQ: LEXX) has, since its inception, remained committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules…